Copyright
©The Author(s) 2019.
World J Gastroenterol. Mar 14, 2019; 25(10): 1238-1247
Published online Mar 14, 2019. doi: 10.3748/wjg.v25.i10.1238
Published online Mar 14, 2019. doi: 10.3748/wjg.v25.i10.1238
Overall (n = 1303) | Recurrence (107) | No recurrence (1196) | OR (95%CI) | P-value | |
Gender | |||||
Male | 681 (52.3) | 65 (60.7) | 616 (51.5) | ||
Female | 622 (47.7) | 42 (39.3) | 580 (48.5) | 0.686 (0.458, 1.028) | 0.067 |
Age (yr) | |||||
Mean (SD) | 55.77 (13.696) | 55.76 (0.390) | 55.83 (1.538) | 1.000 (0.986, 1.015) | 0.276 |
Tumor location | |||||
Gastric | 873 (67.0) | 38 (35.5) | 835 (69.8) | ||
Non-gastric | 430 (33.0) | 69 (64.5) | 361 (30.2) | 4.200 (2.774, 6.359) | < 0.05 |
Follow-up period (mo) | |||||
Mean (SD) | 64.91 (35.793) | 75.36 (4.608) | 63.98 (0.995) | 1.008 (1.003, 1.013) | < 0.05 |
Tumor size | |||||
Mean (SD) | 5.14 (4.862) | 9.01 (0.663) | 4.80 (0.130) | 1.128 (1.092, 1.165) | < 0.05 |
≤ 5 cm | 775 (59.5) | 28 (26.2) | 747 (62.5) | ||
> 5 cm | 528 (40.5) | 79 (73.8) | 449 (37.5) | 4.694 (3.003, 7.337) | < 0.05 |
Mitotic index | |||||
≤ 5/50 HPFs | 877 (67.3) | 44 (41.1) | 833 (69.6) | ||
> 5/50 HPFs | 426 (32.7) | 63 (58.9) | 363 (30.4) | 3.286 (2.193, 4.923) | < 0.05 |
Tumor rupture | |||||
Yes | 34 (2.6) | 27 (25.2) | 7 (0.6) | 57.327 (24.220, 135.685) | |
No | 1269 (97.4) | 80 (74.8) | 1189 (99.4) | < 0.05 | |
Modified NIH | |||||
Very low risk | 347 (26.6) | 14 (13.10) | 333 (27.80) | 0.182 (0.101, 0.329) | < 0.05 |
Low risk | 394 (30.2) | 10 (9.30) | 384 (32.10) | 0.113 (0.057, 0.222) | < 0.05 |
Intermediate risk | 162 (12.4) | 8 (7.50) | 154 (12.90) | 0.225 (0.106, 0.478) | < 0.05 |
High risk | 400 (30.7) | 75 (70.10) | 325 (27.20) | ||
AFIP criteria | |||||
Very low risk | 619 (47.5) | 15 (14.00) | 604 (50.50) | 0.081 (0.045, 0.146) | < 0.05 |
Low risk | 250 (19.2) | 16 (15.00) | 234 (19.60) | 0.224 (0.125, 0.401) | < 0.05 |
Intermediate risk | 173 (13.3) | 15 (14.00) | 158 (13.20) | 0.311 (0.170, 0.568) | < 0.05 |
High risk | 261 (20.0) | 61 (57.00) | 200 (16.70) |
Difference (95%CI) | P-value | |
AFIP-MAP | 0.3485 | 0.7275 |
AFIP-MSKCC_2 yr | -0.2933 | 0.7693 |
AFIP-MSKCC_5 yr | 0.5597 | 0.5757 |
AFIP-Modified NIH | 4.2594 | < 0.05 |
MAP-MSKCC_2 yr | -0.4296 | 0.6675 |
MAP-MSKCC_5 yr | 0.3559 | 0.7219 |
MAP-Modified NIH | 1.7202 | 0.0854 |
MSKCC_2 yr-MSKCC_5 yr | 0.7895 | 0.4298 |
MSKCC_2 yr-Modified NIH | 1.2829 | 0.1995 |
MSKCC_5 yr-Modified NIH | 0.5711 | 0.5679 |
- Citation: Chen T, Ye LY, Feng XY, Qiu HB, Zhang P, Luo YX, Yuan LY, Chen XH, Hu YF, Liu H, Li Y, Tao KX, Yu J, Li GX. Performance of risk stratification systems for gastrointestinal stromal tumors: A multicenter study. World J Gastroenterol 2019; 25(10): 1238-1247
- URL: https://www.wjgnet.com/1007-9327/full/v25/i10/1238.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i10.1238